ArticleSynthetic and systems biotechnology2018
Engineering metabolic pathways in
Article in Synthetic and systems biotechnology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 21 citations in OpenAlex.
- Multiple regulators control the biosynthesis of brasilicardin in Nocardia terpenica.Applied microbiology and biotechnology · 2025Article
- Actinomycetes as Producers of Biologically Active Terpenoids: Current Trends and Patents.Pharmaceuticals (Basel, Switzerland) · 2023Review
- GC-MS and UHPLC-QTOFMS-assisted identification of the differential metabolites and metabolic pathways in key tissues ofFrontiers in plant science · 2023Article
- Genome Assembly and Genetic Traits of the Pleuromutilin-ProducerJournal of fungi (Basel, Switzerland) · 2022Article
- Genetic Engineering in Combination with Semi-Synthesis Leads to a New Route for Gram-Scale Production of the Immunosuppressive Natural Product Brasilicardin A.Angewandte Chemie (International ed. in English) · 2021Article
- Bacterial terpenome.Natural product reports · 2021Review
- A novel LysR-type regulator negatively affects biosynthesis of the immunosuppressant brasilicardin.Engineering in life sciences · 2021Article
- Bioactive molecules from Nocardia: diversity, bioactivities and biosynthesis.Journal of industrial microbiology & biotechnology · 2019Review
- Enhancement of precursor amino acid supplies for improving bacitracin production by activation of branched chain amino acid transporter BrnQ and deletion of its regulator geneSynthetic and systems biotechnology · 2018Article
- Metabolic pathway engineering.Synthetic and systems biotechnology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The isoprenoid brasilicardin A is a promising immunosuppressant compound with a unique mode of action, high potency and reduced toxicity compared to today's standard drugs. However, production of brasilicardin has been hampered since the producer strain
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.